A Revised CAR T for Lymphoma Has Fewer Side Effects
A Revised CAR T for Lymphoma Has Fewer Side Effects
An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.
A Revised CAR T for Lymphoma Has Fewer Side Effects
A Revised CAR T for Lymphoma Has Fewer Side Effects

An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.

An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.

lymphoma
Genetic Screen Predicts T-Cell Lymphoma Aggression
Genetic Screen Predicts T-Cell Lymphoma Aggression
Kerry Grens | May 9, 2018
Sequencing of a single gene can spot patients with a dangerous form of mycosis fungoides better than other prognostic tests.  
FDA Approves Second CAR T-Cell Therapy
FDA Approves Second CAR T-Cell Therapy
Ashley P. Taylor | Oct 19, 2017
The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B-cell lymphomas.